Compound heterozygous female with fragile X syndrome

Mary G. Linden, Flora Tassone, Louise W. Gane, Jennifer L. Hills, Randi J Hagerman, Annette K. Taylor

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We report on a 15-year-old compound heterozygous young woman with fragile X syndrome who has a full mutation of 363 repeats on one X chromosome and a premutation of 103 repeats on the other X chromosome. As predicted, subsequent testing demonstrated that her father carries a premutation (98 repeats) as does her mother (146 repeats). There is only one previous report of a compound heterozygous female with fragile X syndrome. By quantitation of Southern blot signals, the activation ratio for the premutation (the proportion of the premutation on the active X chromosome) was determined to be 0.78. Immunocytochemistry of blood smears showed fragile X mental retardation-1 protein (FMRP) expression in 63.5% of lymphocytes. Cognitively, this woman is functioning in the mid-range of involvement for fragile X females. She attends regular classes and receives supplemental assistance for her learning disabilities. She experiences behavior characteristics typical of females with fragile X syndrome including severe shyness, anxiety, panic episodes, mood swings, and attention deficits. She has responded very well to appropriate treatment including fluoxetine for anxiety, methylphenidate for attentional problems, and educational therapy.

Original languageEnglish (US)
Pages (from-to)318-321
Number of pages4
JournalAmerican Journal of Medical Genetics
Volume83
Issue number4
DOIs
StatePublished - Apr 2 1999
Externally publishedYes

Fingerprint

Fragile X Syndrome
X Chromosome
Anxiety
Fragile X Mental Retardation Protein
Shyness
Methylphenidate
Panic
Fluoxetine
Learning Disorders
Southern Blotting
Fathers
Immunohistochemistry
Mothers
Lymphocytes
Mutation
Therapeutics

Keywords

  • Activation ratio
  • Compound heterozygote
  • FMRP
  • Fragile X syndrome
  • Full mutation
  • Mental retardation
  • Premutation

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Compound heterozygous female with fragile X syndrome. / Linden, Mary G.; Tassone, Flora; Gane, Louise W.; Hills, Jennifer L.; Hagerman, Randi J; Taylor, Annette K.

In: American Journal of Medical Genetics, Vol. 83, No. 4, 02.04.1999, p. 318-321.

Research output: Contribution to journalArticle

Linden, Mary G. ; Tassone, Flora ; Gane, Louise W. ; Hills, Jennifer L. ; Hagerman, Randi J ; Taylor, Annette K. / Compound heterozygous female with fragile X syndrome. In: American Journal of Medical Genetics. 1999 ; Vol. 83, No. 4. pp. 318-321.
@article{7808f88d10c749838945de762f09c949,
title = "Compound heterozygous female with fragile X syndrome",
abstract = "We report on a 15-year-old compound heterozygous young woman with fragile X syndrome who has a full mutation of 363 repeats on one X chromosome and a premutation of 103 repeats on the other X chromosome. As predicted, subsequent testing demonstrated that her father carries a premutation (98 repeats) as does her mother (146 repeats). There is only one previous report of a compound heterozygous female with fragile X syndrome. By quantitation of Southern blot signals, the activation ratio for the premutation (the proportion of the premutation on the active X chromosome) was determined to be 0.78. Immunocytochemistry of blood smears showed fragile X mental retardation-1 protein (FMRP) expression in 63.5{\%} of lymphocytes. Cognitively, this woman is functioning in the mid-range of involvement for fragile X females. She attends regular classes and receives supplemental assistance for her learning disabilities. She experiences behavior characteristics typical of females with fragile X syndrome including severe shyness, anxiety, panic episodes, mood swings, and attention deficits. She has responded very well to appropriate treatment including fluoxetine for anxiety, methylphenidate for attentional problems, and educational therapy.",
keywords = "Activation ratio, Compound heterozygote, FMRP, Fragile X syndrome, Full mutation, Mental retardation, Premutation",
author = "Linden, {Mary G.} and Flora Tassone and Gane, {Louise W.} and Hills, {Jennifer L.} and Hagerman, {Randi J} and Taylor, {Annette K.}",
year = "1999",
month = "4",
day = "2",
doi = "10.1002/(SICI)1096-8628(19990402)83:4<318::AID-AJMG16>3.0.CO;2-Y",
language = "English (US)",
volume = "83",
pages = "318--321",
journal = "American Journal of Medical Genetics",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Compound heterozygous female with fragile X syndrome

AU - Linden, Mary G.

AU - Tassone, Flora

AU - Gane, Louise W.

AU - Hills, Jennifer L.

AU - Hagerman, Randi J

AU - Taylor, Annette K.

PY - 1999/4/2

Y1 - 1999/4/2

N2 - We report on a 15-year-old compound heterozygous young woman with fragile X syndrome who has a full mutation of 363 repeats on one X chromosome and a premutation of 103 repeats on the other X chromosome. As predicted, subsequent testing demonstrated that her father carries a premutation (98 repeats) as does her mother (146 repeats). There is only one previous report of a compound heterozygous female with fragile X syndrome. By quantitation of Southern blot signals, the activation ratio for the premutation (the proportion of the premutation on the active X chromosome) was determined to be 0.78. Immunocytochemistry of blood smears showed fragile X mental retardation-1 protein (FMRP) expression in 63.5% of lymphocytes. Cognitively, this woman is functioning in the mid-range of involvement for fragile X females. She attends regular classes and receives supplemental assistance for her learning disabilities. She experiences behavior characteristics typical of females with fragile X syndrome including severe shyness, anxiety, panic episodes, mood swings, and attention deficits. She has responded very well to appropriate treatment including fluoxetine for anxiety, methylphenidate for attentional problems, and educational therapy.

AB - We report on a 15-year-old compound heterozygous young woman with fragile X syndrome who has a full mutation of 363 repeats on one X chromosome and a premutation of 103 repeats on the other X chromosome. As predicted, subsequent testing demonstrated that her father carries a premutation (98 repeats) as does her mother (146 repeats). There is only one previous report of a compound heterozygous female with fragile X syndrome. By quantitation of Southern blot signals, the activation ratio for the premutation (the proportion of the premutation on the active X chromosome) was determined to be 0.78. Immunocytochemistry of blood smears showed fragile X mental retardation-1 protein (FMRP) expression in 63.5% of lymphocytes. Cognitively, this woman is functioning in the mid-range of involvement for fragile X females. She attends regular classes and receives supplemental assistance for her learning disabilities. She experiences behavior characteristics typical of females with fragile X syndrome including severe shyness, anxiety, panic episodes, mood swings, and attention deficits. She has responded very well to appropriate treatment including fluoxetine for anxiety, methylphenidate for attentional problems, and educational therapy.

KW - Activation ratio

KW - Compound heterozygote

KW - FMRP

KW - Fragile X syndrome

KW - Full mutation

KW - Mental retardation

KW - Premutation

UR - http://www.scopus.com/inward/record.url?scp=0033515685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033515685&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-8628(19990402)83:4<318::AID-AJMG16>3.0.CO;2-Y

DO - 10.1002/(SICI)1096-8628(19990402)83:4<318::AID-AJMG16>3.0.CO;2-Y

M3 - Article

C2 - 10208169

AN - SCOPUS:0033515685

VL - 83

SP - 318

EP - 321

JO - American Journal of Medical Genetics

JF - American Journal of Medical Genetics

SN - 1552-4825

IS - 4

ER -